ANP presenting now, page-75

I guess at the end of the day it's all about inflammation.

Antisense ATL1102 is a n inhibitor of CD49d (disease progression biomarker)
"
ATL1102 has much broader scope which could lead Antisense to target not only a bigger slice of the DMD market, as well as the US$17 billion steroid and the US$106 billion anti-inflammatory market – keeping in mind that ATL1102 may provide a much safer alternative to steroid-based therapies. With its unique mechanism of action, ATL1102 may also be used in combination with existing DMD treatmentson the market (such as Exondys 51) and those therapies presently in clinical development. "

Maybe we can help.....